PAIGE REED: Open Payments
NPI 1417679168 · NEWTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,139 in 67 payments from 14 companies in 2025. Trend: 2023 $1,208 · 2024 $1,417 · 2025 $1,139
Food & beverage: $1,139
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $204 |
| ABBVIE INC. | 13 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $188 |
| Otsuka America Pharmaceutical, Inc. | 9 | $167 |
| Lundbeck LLC | 5 | $77 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Neurocrine BioSciences, Inc. | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| E.R. Squibb & Sons, L.L.C. | 2 | $30 |
| MDD US Operations, LLC | 2 | $29 |
Products named: VRAYLAR, CAPLYTA, ARISTADA, REXULTI, FANAPT, INGREZZA, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
